Clinical experience with the heat shock protein-90 inhibitor, tanespimycin, in patients with relapsed lymphoma

Leuk Lymphoma. 2012 May;53(5):990-2. doi: 10.3109/10428194.2011.631236. Epub 2012 Mar 13.
No abstract available

Publication types

  • Clinical Trial, Phase II
  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Benzoquinones / therapeutic use*
  • Drug-Related Side Effects and Adverse Reactions
  • Female
  • HSP90 Heat-Shock Proteins / antagonists & inhibitors*
  • Humans
  • Lactams, Macrocyclic / therapeutic use*
  • Lymphoma / drug therapy*
  • Male
  • Middle Aged
  • Recurrence
  • Salvage Therapy / methods*
  • Treatment Outcome

Substances

  • Benzoquinones
  • HSP90 Heat-Shock Proteins
  • Lactams, Macrocyclic
  • tanespimycin